FibroBiologics (FBLG) Net Income (2023 - 2026)
FibroBiologics (FBLG) posted quarterly Net Income of -$5.6 million for Q2 2026, up 26.41% year-over-year from -$4.4 million in Q2 2025, and up 26.44% on a QoQ basis from -$7.6 million in Q1 2026.
FibroBiologics (FBLG) Net Income (2023 - 2026) Analysis & Trends
FibroBiologics has reported Net Income for 4 years, with the latest figure at -$5.6 million in Q2 2026.
- Net Income for Q2 2026 came in at -$5.6 million, up 26.41% year-over-year; the trailing twelve-month figure through Jun 2026 was -$23.7 million (down 1.72% YoY), and the FY2025 annual result was -$25.6 million, down 36.76% from the prior year.
- Net Income rose to -$5.6 million in Q2 2026, from -$7.6 million in the prior quarter.
- Over five years, Net Income peaked at -$1.9 million in Q3 2023 and troughed at -$7.9 million in Q3 2025.
- A 4-year average of -$4.5 million and a median of -$3.5 million in 2024 frame the typical range for Net Income.
- The widest annual swing landed in 2024, when Net Income slumped 230.15%; it then climbed 26.41% in 2026.
- A 4-year view of Net Income shows it stood at -$2.6 million in 2023, then plunged by 39.19% to -$3.7 million in 2024, then climbed by 24.38% to -$2.8 million in 2025, then tumbled by 101.16% to -$5.6 million in 2026.
- Per Business Quant data, the three most recent Net Income figures were -$5.6 million in Q2 2026, -$7.6 million in Q1 2026, and -$2.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - | -4.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.56 Mn |
| Mar 31, 2026 | -7.56 Mn |
| Dec 31, 2025 | -2.76 Mn |
| Sep 30, 2025 | -7.87 Mn |
| Jun 30, 2025 | -5.02 Mn |
| Mar 31, 2025 | -5.84 Mn |
| Dec 31, 2024 | -3.66 Mn |
| Sep 30, 2024 | -6.30 Mn |
| Jun 30, 2024 | -3.16 Mn |
| Mar 31, 2024 | -3.42 Mn |
| Dec 31, 2023 | -2.48 Mn |
| Sep 30, 2023 | -2.05 Mn |
| Jun 30, 2023 | -2.10 Mn |
| Mar 31, 2023 | -2.40 Mn |